Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zi Shen Qing (ZSQ) is a traditional Chinese herbal medicine formula used primarily for the treatment of mild-to-moderate systemic lupus erythematosus (SLE), particularly in patients with the "Deficiency of Qi and Yin" pattern as defined by Traditional Chinese Medicine. Clinical studies have shown that ZSQ can significantly reduce SLE disease activity, lower corticosteroid requirements, and decrease the incidence of disease flare-ups compared to standard therapy. The formula is considered safe with no serious adverse events reported in clinical trials; laboratory indices such as blood counts and liver/renal function remained normal during treatment. The precise mechanism of action is not fully elucidated but is believed to involve immunomodulation and anti-inflammatory effects through multiple herbal components[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zi Shen Qing.